|

Investigator's choice of TKI Clinical Trials

1 actively recruiting trial across 1 location

Pipeline

Phase 3: 1

Top Sponsors

  • Ascentage Pharma Group Inc.1

Indications

  • Leukemia, Lymphoblastic, Acute, Philadelphia-Positive1
  • Ph+ ALL1
  • Cancer1

Birmingham, Alabama1 trial

A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1)

Ascentage Investigative Site #1044

Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.